Introduction
The BXSB mouse is a recombinant inbred strain 1 that provides a model of the proliferative glomerulonephritis observed in human systemic lupus erythematosus (SLE). This strain develops a range of autoantibodies directed at nuclear components, particularly anti-DNA and antichromatin. 2 Alongside this spectrum of autoantibodies, more general indicators of immune system dysregulation can be observed, specifically splenomegaly and lymphadenopathy. 1 The culmination of disease occurs in the kidneys, where mesangial matrix increase and cellular infiltration are observed as characteristic features of the glomerulonephritis in the BXSB strain. 2 Genetic studies in both mouse models and human populations have indicated that SLE is a complex genetic disease; thus, multiple loci contribute to disease susceptibility, with no absolute requirement for any single locus. 3 Comparison of the many linkage studies performed in the lupus prone mouse strains, MRL, BXSB and (NZB Â NZW)F 1 , amply illustrates the complexity of this disease. 4 Some chromosomal intervals have been consistently linked to SLE in different models, particularly distal chromosome 1. [5] [6] [7] However, it is also clear that several other intervals, unique to each mouse model, play crucial roles in the development of disease. For example, in BXSB mice, Bxs1 on chromosome 1 is now known to be an important locus for the development of nephritis, 8, 9 but this interval is not linked to disease in either the (NZB Â NZW)F 1 or MRL models. 10, 11 Identification of the genetic basis of these disease-susceptibility intervals is fundamental to developing our understanding of this prototypic autoimmune disease.
In BXSB mice, in addition to the autosomal loci, the Ychromosome carries an autoimmune accelerator gene (Yaa). 12 Though the identity of this gene is still unclear, it has been demonstrated to accelerate disease observed in BXSB male mice in comparison to their female counterparts. 12 Transfer of the BXSB Y-chromosome by breeding onto other autoimmune prone strains of mice, such as NZB and NZW, has been shown to accelerate disease progression. 13 It has only recently become clear that Yaa is capable of breaking tolerance in a non-autoimmune prone strain such as C57BL/10 (B10). 8 Whereas linkage studies are invaluable for identifying chromosomal intervals in which disease-susceptibility loci are located, they are limited in their resolution. The resultant disease-associated interval may contain several hundred positional candidate genes, of which several may present as reasonable functional candidates. In order to confirm our linkage data, we generated congenic mice, in which the disease-associated intervals of chromosome 1 were bred onto a non-autoimmune strain (B10) containing the Yaa gene. 8 Thus, the individual and isolated contribution of each linkage region to the overall phenotype could be interrogated. These novel mouse strains present a restricted and defined genetic resource, with minimal genetic variation from the non-affected B10 parental strain, and each interval contributes different aspects of the overall phenotype 8 ( Figure 1 ). The next stage to dissecting the genetic basis of SLE is the identification of candidate genes. One approach is to select genes that are differentially expressed between congenic and control strains. Given the large number of potential candidates, even within the congenic intervals, microarrays offer a rapid way of screening for expression level differences. Although expression profiling may not identify functional differences underlying the disease, it may detect perturbations in downstream expression levels secondary to the primary genetic defects on chromosome 1. Such a 'disease pathway' may be identified by examining gene expression in those strains with related phenotypes and determining any common differentially expressed genes.
A major problem in the expression profiling approach is the large number of candidates that may be identified. These congenic strains provide an ideal resource to Figure 1 Schematic representation of chromosome 1 BXSB congenic mouse strains. The microsatellite markers used to direct the breeding for each strain are shown on the left-hand side (scale in Mb). Disease-susceptibility linkage intervals are indicated by grey boxes and named according to Hogarth et al. 7 and Haywood et al. 9 The congenic interval is indicated by the dark grey bar, and the pale grey bars indicate regions in which the location of genetic recombination remains to be determined. Thus, the B10.Yaa.Bxs1 strain contains the BXSB-derived interval from 46. reduce background in such an analysis. 14, 15 Each congenic interval is relatively small in comparison to the whole genome, so the confounding influence of natural variations between strains can be minimised. In addition, each congenic interval partially overlaps with at least one of the other strains. Thus, the validity of candidate genes can, in part, be determined by the expression profile across the strains. By definition, a differentially expressed candidate gene should be expressed at a similar level in all strains containing the BXSB allele of that gene, and must be differentially expressed in all strains carrying the B10 allele. To this end, we have carried out an extensive microarray analysis on all four congenic strains together with B10.Yaa, B10 and BXSB as controls, to direct our future studies.
B10.Yaa.Bxs2/3 mice develop a phenotype that is closest to the parental BXSB strain, though with later onset, 12 months for 50% mortality compared to 6 months for BXSB. 8 This congenic strain displays accelerated mortality, a broad spectrum of autoantibodies and age-dependent glomerulonephritis with focal mesangial hypercellularity accompanied by a matrix increase that was qualitatively similar to the lesions observed in BXSB mice.
8 B10.Yaa.Bxs1/4 mice also developed similar nephritic lesions, along with a broad spectrum of autoantibodies, but the onset was later still (12 months mortality 25%).
8 B10.Yaa.Bxs1 mice developed glomerulonephritis in the absence of autoantibodies, whereas B10.Yaa.Bxs1/2 mice developed autoantibodies without concomitant nephritis.
Results

Congenic mice as a microarray resource
The congenic strains examined in this study have considerable overlaps with each other (Figure 1 ). Each congenic strain contained between 2.6 and 4.4% of the BXSB autosome. In addition, each strain was consomic for the BXSB Y-chromosome. In parental BXSB mice, disease onset, as measured by the severity of glomerulonephritis, was not detectable prior to 2 months of age, and thus congenic strains were sampled at this time point to obtain material for microarray analysis.
In autoimmune diseases, it is likely that multiple cell types play a role in disease; however, the effect of any individual locus, as contained in the congenic mice, may be restricted to a particular cell type. We chose to profile splenocytes by reason that the major immune cell types, B cells, T cells and macrophages, would be present in our samples. In any gene expression analysis, it is crucial that the cellular profile of samples should be as closely matched as possible. Fluorescence-activated cell sorting (FACS) analysis was used to eliminate mice that showed abnormal cellular profiles, such as elevated macrophage counts, which may occur as a result of infection. No mice were excluded from the B10.Yaa.Bxs1/4 or B10.Yaa cohorts, one was excluded from the B10.Yaa.Bxs1 cohort, two each were excluded from the B10, B10.Yaa.Bxs1/2 and BXSB cohorts, and three from the B10.Yaa.Bxs2/3 cohort, all on the basis of elevated macrophage counts (percentage Mac-1-stained cells 45.5%). Our detailed phenotype study of these mice revealed that there was an age-associated increase in B220 þ cells in the B10.Yaa.Bxs1/4 and B10.Yaa.Bxs2/3 strains, and monocytosis in B10.Yaa.Bxs2/3. 8 However, the samples used for the gene expression analysis presented here were collected prior to this change and to the development of disease.
Overlapping congenic intervals aid identification of novel candidate genes Over-and underexpressed probes for each congenic strain were identified using the arbitrary level of twofold change in expression levels with respect to B10. 16, 17 The results for each congenic strain were overlapped with those for both BXSB and B10.Yaa mice. This allowed us to identify the primary genetic causes of lupus attributable to the specific chromosome 1 congenic interval rather than effects associated with Yaa. Our results therefore show those genes with altered expression levels in both the congenic line and BXSB, but not in B10.Yaa. All differentially expressed probe sequences were BLAST searched using NCBI Genome Blast (http://www.ncbi.-nih.gov/entrez/) to identify chromosomal locations for each sequence, and checked against the Ensembl database. As many Affymetrix probe sequences originated from complementary DNA (cDNA) sequences, NCBI Unigene was used to identify the genes represented by some probes. Differentially expressed sequences that were located on chromosome 1 were plotted with respect to the congenic intervals on chromosome 1 (Figures 2 and 3 ).
X Kell Blood Group 4-related protein is a candidate for Bxs4 B10.Yaa.Bxs1/4 mice developed a wide spectrum of autoantibodies at high titres, in addition to nephritis associated with the Bxs1 locus. 8 Candidate genes for the Bxs4 autoantibody-susceptibility locus must map to the interval specific to B10.Yaa.Bxs1/4, excluding any overlap with B10.Yaa.Bxs1, that is, from the centromere to D1Mit235 (46.8 Mb) (Figure 1 ). Bxs4 candidates can only be differentially expressed in the B10.Yaa.Bxs1/4 congenic. Any sequences mapping to the interval between D1Mit212 (40.6 Mb) and D1Mit235 cannot be excluded from consideration, because we are uncertain how much of this interval is present in B10.Yaa.Bxs1. The interval from the centromere to D1Mit235 contains some 198 known genes (Ensembl v32), of which 132 (66.7%) were interrogated by the Affymetrix MG-U74v2 chipset.
In the Bxs4 target interval, we identified three overexpressed and 10 underexpressed sequences (Figures 2  and 3 ). However, only one of these candidates (AI854359) remained after comparison between the multiple congenic strains when analysed using Genespring, illustrating the power of the overlapping congenic approach. AI854359, a clone that is the mouse homologue of the Human X Kell Blood Group 4-related protein (Xkr4), was 3.8-fold underexpressed (P ¼ 0.033) in B10.Yaa.Bxs1/4 mice. We have confirmed this result using real-time polymerase chain reaction (PCR) (data normalised to B10 ¼ 170.30, BXSB ¼ 0.00470.002, B10.Yaa.Bxs1/ 4 ¼ 0.02070.010). A further candidate was identified using the significance analysis method (SAM) analysis approach, valosin containing protein complex interacting protein (Vcpip1) at 9.8 Mb, which was downregulated only in B10.Yaa.Bxs1/4 mice. We did not obtain a consensus between the two analysis methods on any of the possible genes in this region.
The Bxs3 interval contains two candidate genes, Gas5 and Ifi202 B10.Yaa.Bxs2/3 mice contain the powerful lupus interval, Bxs3. These mice rapidly develop severe disease. 8 In contrast, the overlapping congenic strain, B10.Yaa.Bxs1/2, develops only late-onset, moderate titre, anti-doublestranded DNA (dsDNA) antibodies with no concomitant nephritis. 8 The phenotypic overlap of these strains therefore localises Bxs3 to the interval between D1Mit33 (161.9 Mb) and the telomere. There are approximately 330 known genes in the Bxs3 interval, of which 239 (72.4%) were represented on the microarray.
Two candidate genes were identified for this interval (Table 1) , each highlighted by two separate probes in the fold-change analysis: interferon inducible 202 (Ifi202) and growth arrest specific 5 (Gas5). The two probes for Ifi202 (177.83 Mb) showed between 6.8-and 11.5-(Po0.05) fold overexpression in the congenic mouse compared to control B10, consistent with the greater than 10-fold overexpression of Ifi202 identified in NZB mice.
15 Gas5 (164.6 Mb) was underexpressed at between 3.3-and 13.5-fold (Po0.05) in congenic B10.Yaa.Bxs2/3 mice and comparably in BXSB (À3.5 to À12.5 fold, Po0.05). This gene has not previously been implicated in the pathogenesis of SLE. All other candidates were eliminated on Figure 2 Overexpressed sequences mapping to chromosome 1. Each sequence is denoted by the Gene name or Genbank accession number. The number in brackets indicates the level of fold change for each probe (where two values are shown, it indicates the results for two probes representing the same gene). All genes with twofold or greater change are depicted, those for which the t-test P-value o0.1 are shown in bold, with a black bar indicating the location of the gene, other probes are shown with a grey bar. For each congenic interval the marker-delineated interval selected during breeding is shown in dark grey, and the margins of each congenic are shown in pale grey. Genes which are underlined have altered expression levels in more than one congenic strain.
the basis of inappropriate expression patterns across the congenic strain panel, for example, Cd84, or high t-test Pvalues (P40.1) indicating unreliable or inconsistent data, for example, Hnrpu.
The SAM analysis also identified one of the Gas5 probes (98531_g_at) as significantly differently expressed, confirming this result. We did not confirm the Ifi202 probe result by this second method; however, we did identify probe 115624_at, which lies in the closely related Ifi203. Our investigations into the complex Ifi family of genes are continuing. SAM analysis identified four further probes located in this region that showed significant differences in B10.Yaa.Bxs2/3 mice. Three were downregulated, Bat2d (104782_at), Cdca1 (135371_at) and Sdccag8 (116178_at), and one was upregulated (112013_at), for which there is no identified gene.
Bxs2-driven anti-double-stranded DNA antibody production was associated with three underexpressed sequences B10.Yaa.Bxs1/2 mice, in common with B10.Yaa.Bxs2/3, develop an enhanced level of anti-dsDNA antibodies, but do not develop nephritis or a wider spectrum of autoantibodies. The overlapping B10.Yaa.Bxs1 strain does not develop anti-dsDNA antibodies. Thus, this phenotypic trait maps to the overlap between B10.Yaa.Bxs1/2 and B10.Yaa.Bxs2/3, namely D1Mit305 (90.7 Mb) to 
D1Mit107 (165.9 Mb).
8 This is a large region of approximately 74 Mb containing 631 known genes, of which 425 (67.3%) were assayed here (Figures 2 and 3) .
Comparison of the B10.Yaa.Bxs1/2 and B10.Yaa.Bxs2/3 strains by fold change analysis revealed three underexpressed sequences that satisfied our screening criteria and no overexpressed sequences ( Table 2) . Two of these probes represented expressed sequence tags (ESTs), AI427984 and AA756546. The former showed 50% homology at a protein level to Mus musculus immunoglobulin E-binding protein, while the latter was originally derived from a thymus library and lies approximately 60 kb 5 0 upstream of sterol O-acyltransferase (Soat1). The remaining underexpressed probe, Marco, is a macrophage scavenger receptor, 18 which functions to recognise both bacterial cells and apoptotic cells. SAM analysis did not identify these sequences, but did highlight an overexpressed probe (163011_at) that represents a tRNA methyltransferase-like sequence at 151.3 Mb.
No Bxs1 candidate genes
The Bxs1 locus contains a novel BXSB nephritis-susceptibility gene, which is capable of directing the development of nephritis in the absence of significant autoantibody production. 8 This gene must lie in the overlapping interval between D1Mit212 (40.6 Mb) and D1Mit303 (64.5 Mb). This interval contains 109 known genes, of which 80 were interrogated in this study using MG-U74v2 microarrays. Candidate genes for this locus should be differentially expressed in B10.Yaa.Bxs1/4 and B10.Yaa.Bxs1, but not in the partially overlapping B10.Yaa.Bxs1/2 mice, which do not develop nephritis. There were no probes that satisfied these criteria and thus we could not identify a candidate gene for Bxs1, by either method of analysis.
Validation of microarray results
The approach taken in this study was to include probe sets in the analysis, irrespective of Affymetrix flag data. Also, we did not set a lower threshold for the signal intensity, so that all signals were included. However, this necessitated a careful validation of the results. We took two approaches to this validation. Firstly, we designed real-time quantitative PCR assays for the candidate genes. The primers were designed to amplify the region of the gene that was represented by the Affymetrix probe. Secondly, we reasoned that the primary genetic basis of any mRNA expression level difference was likely to be mutation(s) in the promoter of the gene, so we sequenced upstream of the transcription start site of each candidate gene in BXSB and B10 to identify potential sequence differences. We focussed on the two novel candidate genes with known function for this approach.
Real-time quantitative PCR analysis of the Bxs3 candidate, Gas5 (Table 3) , confirmed the underexpression detected by the microarray data (Table 1) , with a downregulation of 11.0-58.1-fold for BXSB and 
Differentially expressed sequences in B10.Yaa.Bxs2/3 and BXSB congenic mice in comparison to B10.Yaa.Bxs1/4, B10.Yaa.Bxs1 and B10.Yaa.Bxs1/2. The BXSB-derived intervals for each congenic strain are given. Only fold changes greater than twofold in magnitude are shown, and the numerical values represent fold change relative to the normalised B10 value of 1, n/c indicates there was no change between the expression level in the congenic strain and B10. The t-test P-value statistic indicates the significance of the variation from a B10 normalised value of 1 for three replicate samples. 
Differentially expressed sequences in B10.Yaa.Bxs1/2, B10.Yaa.Bxs2/3 and BXSB congenic mice in comparison to B10.Yaa.Bxs1/4 and B10.Yaa.Bxs1. Only fold changes greater than twofold in magnitude are shown, and the numerical values represent fold change relative to the normalised B10 value of 1, n/c indicates that there was no change between the expression level in the congenic strain and B10. The t-test Pvalue statistic indicates the significance of the variation from a B10 normalised value of 1 for three replicate samples.
B10.Yaa.Bxs2/3 compared with B10 and the other congenic strains (excluding Gapdh results). Sequence analysis of the promoter of Gas5 spanned 1621 nucleotides upstream of the transcription start site. 19 Six singlenucleotide polymorphisms were observed in BXSB, compared to both B10 and B6, which were identical: À1285 (G in B10, A in BXSB), À1122 (T to G), À314 (G to C), À277 (A to C), À267 (A to T) and À258 (G to A). The polymorphism at À267 was predicted to lead to a loss of an Sp1 consensus-binding site.
The Bxs2 candidate, Marco, was excluded by real-time quantitative PCR (data not shown). Splenic cDNA levels were found to match those observed in the microarray analysis, with B10.Yaa.Bxs2/3 and BXSB levels being consistently lower than B10. However, fluctuations were also observed in the Marco levels in the other chromosome 1 congenic strains and in B10.Yaa, such that lower levels were observed in all the congenic strains. While this does not fully exclude Marco from a role in disease, its candidacy as the Bxs2 allele has been undermined.
Disease phenotype-associated candidate genes
We have previously phenotyped each of the congenic strains presented here. 8 The primary genetic defects leading to the development of the autoimmune phenotype of each congenic strain are attributable to the particular BXSB intervals that they contain. However, there is a convergence of phenotype observed for some strains and it is likely that common downstream pathways are involved in disease expression. We have used our data to look for expression level changes associated with specific aspects of the phenotype (Table 4) . These genes may indicate disease-associated pathways, and may be candidate genes in other lupus mouse models or indeed humans. We selected genes that exceeded the twofold level of expression change in BXSB and in various combinations of congenics according to common shared phenotypic characteristics, for example, nephritis was associated with Bxs2/3, Bxs1/4 and Bxs1, but not with Bxs1/2 intervals, so we examined the data to look for commonly over-or underexpressed genes in the three nephritis-prone strains.
Nephritis-associated candidate genes. B10.Yaa.Bxs2/3, B10.Yaa.Bxs1/4 and B10.Yaa.Bxs1 mice all develop nephritis to varying degrees of severity, 8 whereas B10.Yaa.Bxs1/2 mice do not. The histological changes are qualitatively the same for all three nephritis strains, indicating potential convergence of the disease pathways. Commonly differentially regulated genes in the nephritis-prone congenic strains may indicate components in this pathway.
We have identified by fold change analysis four genes potentially involved in nephritis (Table 4) 
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By contrast, SAM analysis identified a more limited set of nephritis-associated genes; only the underexpression of Als2cl (11038_at, chromosome 9, 113.7 Mb) was detected.
Bxs1-driven nephritis candidate genes. B10.Yaa.Bxs1/4 and B10.Yaa.Bxs1 partially overlap, but are distinct from B10.Yaa.Bxs2/3. Hence, the primary genetic basis of the nephritis associated with Bxs1 may drive an additional set of genes to those associated with a common nephritic pathway. Indeed, we found three overexpressed and six underexpressed probes, that were common to the Bxs1-driven nephritis strains (Table 4) . One of the overexpressed genes, Mast cell protease 6 (Mcp6, chromosome 17 22 ), maps to a region close to the Asbb3 proteinuria locus on chromosome 17. 23 One of the underexpressed genes plays a role in G-protein-coupled receptor protein signalling pathways; Fzd4 mapped to the Nba3 interval on chromosome 7.
24 Jip-1b (chromosome 2) is known to be important for DNA-dependent transcription regulation. Lysosomal trafficking regulator QRT-PCR, quantitative reverse transcriptase-polymerase chain reaction. Gas5 mRNA was measured in BXSB congenic strains, relative to the control B10 strain. The data for the microarray probes for Gas5 are shown for comparison. The fold change relative to B10 is indicated for each strain, with a negative sign indicating down-regulation. (Lyst, also known as the beige protein; 25 chromosome 13) was also downregulated in Bxs1 nephritis. Mutations in the human homologue of Lyst result in Chediak-Higashi Syndrome (OMIM 215000), although the function of the Lyst protein is still unclear. 26 SAM analysis identified just one downregulated sequence mapping to 113.7 Mb on chromosome 9 (111038_at), representing the 3 0 end of the Clasp2 gene, though any potential role for a CLIP-associating protein in nephritis is not immediately apparent.
Specific autoantibody-associated genes. Only two of four of the congenic lines, B10.Yaa.Bxs1/4 and B10.Yaa.Bxs2/3, developed high levels of autoantibodies directed at single-stranded DNA (ssDNA). There were five commonly overexpressed sequences in these strains (Table 4) . AU023384 is a novel transcript derived from Cd11c þ dendritic cells, which maps to a lupus-susceptibility locus identified as Nbwa1 23, 27 and Asbb2, 27 both associated with antinuclear antibody production. Another, Ahi1, is the mouse orthologue of the human Abelson helper proviral integration site, and a third is Ece2, with methyl transferase activity, which mapped close to the anti-dsDNA locus, Lprm5. 28 The remaining two probes represent ESTs. One of the two underexpressed sequences mapped to a known transcript for lipocalininteracting membrane receptor implicated in sterol and hormone transport, while the other is Prkg1 protein kinase, the orthologue of which is known to play a role in platelet activation in humans. Interestingly, Prkg1 maps to the anti-ssDNA specific locus, Nwa2.
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Our second method of analysis based on RMA identified a set of eight significantly underexpressed sequences (data not shown), of which the only candidate gene of any interest was Btla, a B-and T-lymphocyteassociated sequence represented by probe 133663_at and mapping to 44.1 Mb on chromosome 16. This gene is known to play a role in the regulation of B-cell proliferation, and will thus be further studied as a candidate gene.
Antibodies specific for dsDNA were only detected in B10.Yaa.Bxs1/4, B10.Yaa.Bxs1/2 and B10.Yaa.Bxs2/3. Two commonly overexpressed candidate genes were identified along with seven underexpressed sequences (Table 4). Pgrmc2, a progesterone membrane-binding protein, was overexpressed, but the other upregulated sequence (AI839720) did not map to any known or predicted gene, although it showed homology to the Bcl-2 interacting protein, Nip2. Four underexpressed sequences mapped to chromosome 9, although they were not positionally clustered on the chromosome. These were RNA helicase, Dhx30, myotubularin-related protein 1 (Mtm1), bone morphogenic protein (Bmp5) and interleukin enhancer binding factor 3, Ilf3, a nuclear factor of activated T cells. We have previously identified a chromosome 9 lupus-susceptibility interval, Gp1, associated with the production of anti-gp70 immune complexes and anti-dsDNA antibodies centred around 104.7 Mb.
29 Dhx30 (110.68 Mb) is a candidate for Gp1. The remaining underexpressed genes commonly found in strains with anti-dsDNA antibodies included transcription factor, Hes5, actin-binding protein, Fascin and a G protein receptor, Gprc2a-rs2, which mapped to the Lbw5/ Sle3 lupus-susceptibility region 30, 31 implicated in mortality and anti-dsDNA antibody production. There was no overlap between the pathway genes for anti-ssDNA and anti-dsDNA. SAM analysis highlighted that Colec12 (168379_i_at, chromosome 18, 9.9 Mb) was significantly underexpressed; the potential role of Colec12 as a membrane protein with scavenger receptor activity makes it an attractive candidate for further study.
Discussion
The dissection of the mechanisms and pathways involved in complex genetic diseases such as SLE will necessitate several different experimental strategies. Classical genetic studies have been invaluable for defining disease-susceptibility intervals. Subsequently, congenic strains have been successfully used to delineate smaller genetic intervals with the aim of identifying positional candidate genes. [32] [33] [34] Typical congenic intervals contain at least 400-600 known or predicted genes and hence some strategy for prioritisation of candidate genes is essential. The approach that we present here, expression analysis of overlapping congenic strains, provides an excellent method for narrowing the focus even further and identifying differentially expressed positional candidate genes. However, this approach is not without its limitations. Any expression analysis is only as comprehensive as the array on which it is performed and there is a possibility that a disease gene is not included on the array. Furthermore, expression profiling does not readily identify functional changes in proteins. However, differential expression undoubtedly underlies some susceptibility loci 14, 15, 35 and the determination of differentially regulated pathways may aid the identification of any primary functional variant.
The primary aim of this study was the identification of chromosome 1 SLE disease genes. We have successfully identified a number of novel genes as candidates for the BXSB disease-susceptibility loci on chromosome 1, using two very different analysis techniques. A single Bxs4 candidate was identified, Xkr4. The sequence of Xkr4 is highly evolutionarily conserved, and it is homologous to Ced8 from Caenorhabditis elegans. It may function to degrade DNA during apoptosis, in a pathway parallel to the Ced9 pathway. 36 Defects in apoptosis have been demonstrated to affect the availability of autoantigens which drive autoantibody production, 37 and genes in the apoptotic pathway, such as Fas, have been implicated in the development of lupus in the MRL model. 38 The Bxs3 locus is homologous to Nba2 in (NZB Â NZW)F 1 11 and Sle1 in NZM2410, two models based on the New Zealand mouse. 39 The Sle1 interval has subsequently been subdivided into Sle1a, b, c, d and e, 40 indicating the presence of several susceptibility loci within this interval. Ifi202 was identified by microarray analysis as a major candidate susceptibility gene in this interval in the New Zealand model. 15 The replication of Ifi202 overexpression in a second lupus-prone strain, BXSB, indicates that this is indeed a strong candidate for one of the susceptibility loci in this interval, and lends support to the validity of both data sets. It has been suggested that increased expression of Ifi202 transcription factor may contribute to lupus through inhibition of lymphocyte apoptosis. 41 A further novel Bxs3 candidate, Gas5, was also identified. While the function of Gas5 remains unclear, it has been suggested that it plays a role in the cellular decision to enter the apoptotic pathway. 19 The potential loss of an Sp1 binding site from the promoter of the BXSB allele of Gas5 may be the cause of the down regulation. Further work is underway to characterise which splenocytic cell population Gas5 is normally expressed in and the functional relevance of the promoter polymorphisms. We have also identified three potential candidates for Bxs2. One of these candidates, Marco, was not validated by the strict criteria that we set for expression because it showed differential expression, albeit limited, in other strains not carrying the BXSB allele. However, a role for Marco is attractive because of its function in clearance of apoptotic cells. We are looking in greater detail at the tissue specificity of Marco expression, which may explain these results. We did not identify any candidates for Bxs1, and it may be that a functional polymorphism underlies this disease-susceptibility locus.
The use of multiple congenic strains has also allowed us to identify genes that may play a role in specific disease pathways. Thus, 29 genes were identified that were consistently differentially expressed in strains with common phenotypic characteristics by fold change analysis and 12 by SAM analysis. There is limited overlap between these two methods; however, genes such as Ifi202 have been directly confirmed in other strains. 15 Consequently, these methods cannot be looked on as mutually exclusive, but rather complimentary to other methods of analysis. The use of two methods of analysis has allowed us to extract the maximum information from our data set.
Some of these phenotype-related expression differences were found for genes that map to known SLE susceptibility intervals in BXSB, such as Dhx30 in the Gp1 interval. Other genes were identified that map to susceptibility intervals identified in other lupus-prone strains, for example, Rps6ka1, which lies in the NZB/ W-derived Nba1 disease-susceptibility interval, 20 Mcp6 mapping to the Asbb3 locus 23 and Prkg1 in the Nwa2 interval. 6 Thus, we have used data generated in one lupus-prone strain, BXSB, to identify potential candidate genes that may represent strong candidates for aetiological lupus-susceptibility alleles in other lupus models. In addition, we have found a number of novel genes that do not localise with known lupus loci, but are indicative of important physiological pathways.
There is now increasing interest in interferon-regulated target genes that may be involved in the SLE disease process 42 due to the identification of an 'interferon signature' in SLE patients. Several of the candidate genes that we have identified in this study may be implicated in this pathway, and it is likely that general deregulation of the interferon response genes may be as important in murine models of lupus as has been suggested for human lupus. 43 Hence, Ifi202 has been shown to play a negative regulatory role in cell growth and can be induced by interferon. The human orthologue of Rps6ka1 has been shown to be induced by interferon g in peripheral blood mononuclear cells. 42 Both mouse and human mutations in Lyst are associated with reduced NK cell activity and a reduced response to interferon. 26, 44 The failure to detect differential expression of a gene does not preclude it from playing an aetiological role in disease. Functional mutations cannot be detected directly by expression profiling, but may be inferred from downstream perturbations in the expression of specific pathways. Three chromosome 1 genes, which have been previously implicated in the development of SLE, Cr2,
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46 and CRP, 47 showed no change in their expression pattern and we can make no comment on their role in disease. Conversely, differential expression of a gene in all the congenic strains implies that such a gene plays a key role in the disease process per se. We would argue that such a gene is not a primary cause of disease, but reflects an unbalanced physiological pathway. This is exemplified by overexpression of the immunoglobulin genes in all strains, overproduction of antibodies being a characteristic of the disease in all the congenic strains including B10.Yaa. On chromosome 1, this effect was also illustrated by Pdcd1, another gene recently implicated in the development of SLE. 48 Our data therefore support an important role for Pdcd1 in the development of SLE in our strains, but it is not an initial causative factor in BXSB.
This study has sought to extend the use of microarray expression data by placing it into the wider context of murine lupus-susceptibility studies. The overlap of several analytical approaches, classical genetics, phenotypic studies and gene expression analysis, has enabled us to prioritise candidate genes that merit further study.
Materials and methods
Mice
Mice were bred and maintained under identical conditions at Imperial College from original stocks: BXSB from The Jackson Laboratory (Bar Harbor, ME) and B10 from Harlan Olac Ltd (Bicester, UK) as described previously. . [7] [8] [9] The nature of this approach relies upon the use of microsatellite markers to position recombination events. However, it was not possible to position the recombination between the selection markers for each congenic line. Hence, a region of indeterminate origin was created at the end of all congenic intervals, and putative candidate genes in such intervals were also considered. All congenic mice analysed were male, consomic for the BXSB Y-chromosome (Yaa þ ) and free from disease pathogens. Age-matched B10, BXSB and B10-Y BXSB (B10.Yaa) mice were included as controls.
Flow-cytometric analysis
Flow cytometry was performed using two-colour staining of splenocytes, and analysed with a FACSCalibur (BD Biosciences, San Jose, CA, USA). The following antibodies were used: anti-cluster of differentiation (CD)4-fluorescein isothiocyanate (FITC), anti-CD8-phycoerythrin (PE), anti-B220-FITC (RA3-6B2) and anti-CD11b-PE (BD Biosciences Pharmingen, San Diego, CA, USA), along with isotype-matched controls, rat IgG2a-FITC and rat IgG2a-PE (Caltag, Burlingame, CA, USA). Staining was performed in the presence of a saturating concentration of 2.4G2 anti-FcgRII/III mAb. Data were analysed using WinMDI (http://facs.scripps.edu/software.html).
Microarray analysis
At least nine mice for each of the congenic lines and control strains were killed at 2 months of age, before the onset of disease. 8 The spleen was removed, divided and half was snap frozen in liquid nitrogen prior to RNA extraction using Trizol (Invitrogen, Paisley, UK) as per the manufacturer's recommendations. The remaining half was analysed by FACS to determine the CD4/CD8 ratio and macrophage count. Mice that showed any abnormality in either respect were excluded from further analysis. At the age of 2 months, none of the congenic strains show measurable signs of disease; however, any imbalance in the cell populations used for the preparation of RNA for microarray analysis may have given false results. We prepared the individual RNA from nine screened mice for each strain and then randomly assigned three of the RNAs to each of three pools to generate the biological replicates which were applied to three arrays.
All experiments were performed using Affymetrix MG-U74v2 oligonucleotide arrays, A, B and C chips (totalling 36767 probe sets) (http://www.affymetrix. com/products/arrays/specific/mgu74.affx). Total RNA from each sample was used to prepare biotinylated target RNA, with minor modifications from the manufacturer's recommendations. Briefly, 10 mg of RNA was used to generate first-strand cDNA using a T7-linked oligo(dT) primer. After second-strand synthesis, in vitro transcription was performed with biotinylated UTP and CTP (Enzo Diagnostics, Farmingdale, NY, USA), resulting in approximately 100-fold amplification of RNA. A complete description of procedures is available on CSC MRC Web site (http://microarray.csc.mrc.ac.uk/proto cols/Other%20GeneChip%20Protocols/front_page_-whole.htm). The target cDNA generated from each sample was processed as per the manufacturer's recommendations using an Affymetrix GeneChip Instrument System. Spike controls (detailed below) were added to 10 mg fragmented cDNA before overnight hybridisation. Arrays were then washed and stained with streptavidin-PE, before being scanned on an Affymetrix GeneChip scanner (http://www.affymetrix.-com/support/technical/manual/expression_manua-l.affx). Additionally, the quality and amount of starting RNA was confirmed using agarose gel electrophoresis. After scanning, array images were assessed by eye to confirm scanner alignment and the absence of significant bubbles or scratches on the chip surface. 3 0 /5 0 ratios for glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and b-actin were confirmed to be within acceptable limits and Escherichia coli biotin synthetase gene B (bioB) spike controls were found to be present on all chips, with E. coli biotin synthetase gene C (bioC), E. coli biotin synthetase gene D (bioD) and Bacteriophage P1 gene for recombinase protein (cre) also present in increasing intensity. For quality control purposes, data were scaled to a target intensity of 100 using Affymetrix MAS 5.0 array analysis software; scaling factors for all arrays were within acceptable limits, as were background, Q-values and mean intensities.
All subsequent analysis, including normalisation of the data, was carried out using the global scaling method within Genespring (Agilent Technologies UK Limited, Cheshire, UK). Each measurement was divided by the median of all measurements in that sample (calculated using only genes flagged present or marginal). All congenic strains were normalised to the median of the B10 control samples (calculated using only those measurements that had at least a normalised value of 0.01). Values below 0 were set to 0.
Fold change analysis was used to identify probe signals which were more than twofold over-or underexpressed relative to B10 control signals. Absent, marginal or present Affymetrix flag calls were not used in the selection of candidate genes. The likelihood of any gene's expression value being different from B10 was evaluated using the t-test P-value, which gives an indication of the variation between the control data and the test data for all three replicates for each congenic strain. Genes were excluded if they also showed differential expression in B10.Yaa mice to ensure that only congenic effects were measured. This measure was used to exclude potential candidate genes when it indicated that the data were highly variable between the replicate samples (P40.1). 49 This level of cutoff was chosen as a compromise between the false-positive and false-negative rates; however, we felt that, given the importance of positional information with respect to the interpretation of our data, we could deal with a predicted 12% drop in our true positive rate 49 by subsequent analysis.
We further analysed our data using the significance analysis method. 50 Microarray data were extracted from .cel files and normalised using the expresso function of the Affy package 51 in R; 52 in particular, pm/mm correction was performed using the rma option and quantile normalisation was used. After normalisation, significant gene expression between groups was assessed using SAM, 50 a technique which takes into account the variance and absolute magnitude of a gene's expression pattern as opposed to its relative fold change. Furthermore, rather than a (multiple testing corrected) P-value, SAM produces a false detection rate (FDR) value, the crucial difference being that while with a P-value of 0.05 one would expect five false positives for every 100 tests (regardless of the outcome of the tests), an FDR of 0.05 requires 100 positive tests before one expects five of these to be falsely positive and thus avoids the multiple testing correction issue. Significantly differently expressed genes were identified at the minimal FDR at which they were deemed significant.
Real-time quantitative polymerase chain reaction Strain-specific splenocyte cDNA was synthesised from 1 mg RNA using 2 ml oligo dT [12] [13] [14] [15] [16] [17] [18] primer (Invitrogen) and 400 U Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's recommendations and in the presence of 52.8 U RNAGuard (Amersham Biosciences, Amersham, UK). Quantitative real-time PCR was performed using 12.5 ml SYBR Green master mix (Applied Biosystems, Warrington, UK), 2.6 pmol of each primer and 5 ml of cDNA in a total reaction volume of 20 ml. Samples were tested in triplicate using a 96-well reaction optical plate (Applied Biosystems) and run on an Applied Biosystems 7700 Sequence Detection System. Data were analysed using the manufacturer's Sequence Detection software (v1.7a) and Microsoft Excel (Microsoft Corporation, CA, USA). Primers for control genes were: 18SRNA: 843F, CCTGGATACCGCAGCTAGGAA TAA; 936R, CCCCGGCCGTCCCTCTTAATCAT; b-actin: 915F, TGTGACGTTGACATCCGTAAA; 1143R, CCTGCT TGCTGATCCACATCTGC; Ubiquitin c-terminal hydroxylase (Ubc): F, GTTACCACCAAGAAGGTCAAACAG; R, ATCACACCCAAGAACAAGCACAAG; glyceraldehyde-3-phosphate dehydrogenase (Gapdh): 879F, AGGTTGTCT CCTGCGACTTCAACA; 956R, GAAATGAGCTTGACA AAGTT. Primers for the candidate genes Gas5 and Marco were as follows: Gas5: 988F, GTATTAATGGGTCACCT CAAGTGAA; 1115R, CAGTCACTGCATGTCCACTTGT CA; Marco: 1561F, ATCTTTCCAACGCGTCC GGATCAT; 1645R, CAAATTGTCCCCCACTCATTGTTA. A standard curve using 10-fold serial dilutions was included for the control and candidate gene on each plate. Candidate gene results were normalised to the control gene result for each strain, and then normalised to a B10 value of 1. The data shown represent three separate measurements of a pool of three individuals for each strain. These individuals were not the same as used for the microarray analysis, but were age-matched to those samples and screened in a similar way. Multiple control genes were used to overcome any variation in control genes which may confound the result. 53 Candidate gene promoter sequencing Promoter regions of candidate genes were sequenced from male spleen genomic DNA isolated as described previously. 35 Polymerase chain reaction amplification was performed using NH 4 reaction buffer (Bioline, London, UK), 30 mM MgCl 2 (Bioline, London, UK), 4 mM deoxynucleoside triphosphates (Bioline), 0.2 U Biotaq polymerase (Bioline), 6.6 nM each primer and 80 ng DNA. Primers for Gas5 were as follows: F164600667, GAATGCTCGTGTTAGAGGTG; F164601872, AACGA GCCCAGTCAAGGAG; F164602174, GCTTGAGGAGGA GTCTGA; F164602592, AGAGCATGCTGAGTCACCT; R164601393, GTGCCGACGCTAGAGAAAG; R164602380, ACCAGCTTCCAGTGCTTCAG; R164602790, GAGTTG CACATATCCAGCAG; R164603374, TGCTTACATTGCG CTCGCT. All reactions were performed in polypropylene tubes using an MJ Research PTC225 thermocycler (Reno, NV, USA). Samples were denatured at 941C for 3 min and then 30-35 cycles of 941C for 1 min, 55-651C for 1 min and 721C for 1 min. In all, 30-90 ng of PCR amplicon was purified using a PEG precipitation protocol, 54 prior to sequencing using 3.2 pM primer, and BigDye V2.0 terminator mix (Applied Biosystems) for 25 cycles of 951C for 10 s, 501C for 5 s and 601C for 4 min.
Transcription factor binding site prediction Transcription factor binding sites were predicted using TESS (http://www.cbil.upenn.edu/tess) and Matinspector 55 with default parameters.
